- Email: [email protected]
Impact of acne on teens: Results from Harris Interactive poll
P722
P724
Evaluating two different clinical approaches for treating mild to moderate acne Jacqueline Woodruff, MD, Johnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ, United States; Warren Wallo, MS, Johnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ, United States
Patient-reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects Jonathan Weiss, Gwinnett Clinical Research Center, Inc., Snellville, GA, United States; Joseph Fowler, MD, Dermatology Specialists Research, Louisville, KY, United States; Karen Yu, PhD, Dow Pharmaceuticals Sciences Inc., Petaluma, CA, United States; Leonard Swinyer, MD, Dermatology Research Center, Salt Lake City, UT, United States
Acne is a disease of the skin developing in the presence of excess sebum production and clogged hair follicles, beginning as comedones and potentially developing into papules and pustules in mild to moderate conditions. Consistent and continuous use of a daily acne regimen is an important line of therapy to effectively control the acne condition. This study assesses the efficacy of two separate acne treatment regimens following a 12-week clinical study. A single-blind, investigator-masked, randomized, multicenter study was conducted to evaluate the efficacy of a regimen consisting of a retinoid-based acne treatment cream with ancillary cleanser and moisturizing lotion compared to an acne treatment regimen based in benzoyl peroxide and salicylic acid. Assessments were made using clinical evaluations and self-assessment questionnaires at baseline and weeks 2, 4, 8, and 12. A total of 160 males and females 12 to 30 years of age with mild to moderate acne vulgaris completed this study. One treatment group used a regimen with a 10% benzoyl peroxide cleanser, 2% salicylic acid microgel complex, and a 0.5% salicylic acid lotion. A second treatment group used a multiproduct regimen with a retinoid-based cream. Clinical assessments showed improvements in global acne and total lesion counts for both regimens over 12 weeks. The areas of superiority and those parameters with comparable improvements between the two regimens provide dermatologists with valuable insights in designing therapies for specific patients. Commercial support: 100% sponsored by Johnson & Johnson Consumer & Personal Products Worldwide.
Background: Patient-reported assessments are important in evaluating new treatments for acne and a good indicator of increased patient adherence and outcome. Objective: To evaluate the onset and magnitude of improvement achieved with a unique combination of clindamycin phosphate and low concentration benzoyl peroxide (clindamycin-BPO 2.5%) from the subject’s perspective. Methods: Two multicenter double-blind studies in 2813 subjects with moderate to severe acne randomized 2:2:2:1 to receive a combination of clindamycin phosphate (1.2%) and benzoyl peroxide (2.5%), each active ingredient or vehicle, once daily for 12 weeks. Subject Self-Assessment (SSA) of acne severity and degree of improvement were evaluated on a scale from one (clear) to seven (worse) at each postbaseline visit. Subject satisfaction with treatment was evaluated on a scale from one (least satisfied) to ten (most satisfied) at baseline and end of treatment. Results: As early as week 2, a significantly greater number of subjects rated their acne as ‘‘clear’’’ or ‘‘almost clear’’ with clindamycin-BPO 2.5% compared with benzoyl peroxide (P ¼.045) and vehicle (P ¼.002); this difference increased through week 12. At week 12, clindamycin-BPO 2.5% was statistically superior (P\.001 vs all other treatment groups) in the percent of subjects who rated their acne as ‘‘clear’’ or ‘‘almost clear’’ (39.2%) compared with 29.6% on clindamycin phosphate 1.2%, 29.7% on BPO 2.5%, and 16.6% on vehicle. Subjects also reported greater satisfaction with treatment using clindamycin-BPO 2.5% at week 12 than with individual active ingredients or vehicle. The percent of subjects completing the study was highest in the clindamycin-BPO 2.5% group. Conclusions: Based upon patient-reported outcomes, the unique fixed combination clindamycin-BPO 2.5% aqueous gel applied once daily is an effective therapy for subjects with moderate to severe inflammatory and noninflammatory acne. Significant results are seen as early as week 2. By providing rapid and beneficial improvements in acne as perceived by patients, the use of clindamycin-BPO 2.5% may lead to increased patient adherence to treatment and, therefore, to improved clinical outcomes. Commercial support: 100% sponsored by Arcutis Pharmaceuticals Inc.
P723 The effect of Er: glass fractional laser and chemical reconstruction of skin scar (CROSS) method in treatment of acne scars: A simultaneous split-face comparison study HeeJung Kim, MPH, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, SeodaemunGu, South Korea; EunChun Han, MD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; JuHee Lee, MD, PhD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; KwangHoon Lee, MD, PhD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; TaeGyun Kim, MD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea Background: Acne scars are a common skin condition, but treatment of acne scars are a well known challenge for dermatologists. Numerous treatment options have been proposed. However, there has been no well controlled study comparing the efficacy of 1550nm Er: glass laser and the chemical reconstruction of skin scar (CROSS) method. Objective: We designed the study to compare the efficacy of 1550nm Er: glass fractional laser and CROSS method in the treatment of moderate to severe acne scars. Methods: A split-face trial was conducted in 20 patients with moderate to severe acne scars. One side of the face was treated with 1550-nm Er: glass laser and the other side was treated with CROSS method using 100% trichloroacetic acid for 3 months. Overall effects and side effects were monitored during 12 weeks and after the final treatment session using photography with digital camera, folliscope findings, and 10-point scale assessment evaluated by two individual dermatologists. Patient’s subjective self-assessment was also evaluated. Results: After all of the treatment, statistically significant improvement was demonstrated in both sides of the face. There were no significant differences between both treatment options regarding patient satisfaction. However, it was evident that the 1550-nm Er: glass laser had greater effect on rolling scars, while CROSS method had greater effect on icepick scars. Downtime and lasting erythema were much longer remained in CROSS method group. And there were no significant side effects in 1550-nm Er: Glass laser group. Just one pustule formation and one hyperpigmentation were observed in CROSS method group. Conclusions: A 1550-nm Er: glass fractional laser and CROSS method are both well tolerated and effective treatment options for the treatment of acne scars. However, the objective results demonstrated different effects dependent upon the scar type. Therefore, it may be important to consider the type of acne scar preliminary to select the treatment option. Commercial support: None identified.
AB18
J AM ACAD DERMATOL
P725 Impact of acne on teens: Results from Harris Interactive poll Alan Fleischer, Wake Forest University School of Medicine, Winston-Salem, NC, United States Acne often leads to dissatisfaction with one’s personal appearance. A national survey of teens with acne measured the importance of appearance, impact of acne on individuals’ lives, how people treat acne, and level of knowledge about skin care. Subjects were recruited from the Harris Poll Online database. The 2732 US respondents comprised 1327 teens (13-19 yrs of age) and 514 adults (20-40 yrs of age) with acne, 628 parents of teens with acne, and 263 dermatologists. The survey was conducted in December 2007. Most teens (70%) feel pressure to have clear skin. After weight (32%), skin is the physical attribute that 16% say they would most like to change. Those who have had acne say the more severe the acne the more it impacts self-confidence (69% severe/moderate vs 42% mild), mood (54% vs 28%), and feeling of stress (48% vs 24%). Acne tends to have a greater negative impact on girls than boys. Teens with acne are less happy (mild, 83%; severe/moderate, 74%) than teens without acne (86%), but compared to teens without acne they seem to have better grades in school (33% vs 13%) and greater participation in weekly extracurricular activities (91% vs 74%). Although acne is perceived as a health care issue, 56% of all teen subjects and 54% with more severe/moderate acne are not very knowledgeable about skin care. Only 25% of teens with acne have visited a physician and only 14% have seen a dermatologist. When teens do visit a physician, 63% of teens, 74% of parents, and 43% of dermatologists report that parents initiated the first appointment. Teens (89%) and dermatologists (97%) believe that acne is controllable. But dermatologists (91%) view patient compliance as a treatment barrier, and only 2% say patients follow treatment as prescribed. Half of teens who use acne medications (52%) say they adhere to treatment. Physicianepatient communication is considered satisfactory by 46% of teens who have seen a physician; however, 69% of dermatologists are satisfied. These findings suggest a communication gap among teens and physicians. Despite the availability of improved, effective therapeutic agents, teens continue to suffer the negative impact of acne on quality of life and social relationships. Better communication may help to increase compliance and reduce the impact of acne. Commercial support: Harris Interactive Poll sponsored by OrthoNeutrogena; poster printing costs sponsored by OrthoNeutrogena.
MARCH 2009
P724
Evaluating two different clinical approaches for treating mild to moderate acne Jacqueline Woodruff, MD, Johnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ, United States; Warren Wallo, MS, Johnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ, United States
Patient-reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects Jonathan Weiss, Gwinnett Clinical Research Center, Inc., Snellville, GA, United States; Joseph Fowler, MD, Dermatology Specialists Research, Louisville, KY, United States; Karen Yu, PhD, Dow Pharmaceuticals Sciences Inc., Petaluma, CA, United States; Leonard Swinyer, MD, Dermatology Research Center, Salt Lake City, UT, United States
Acne is a disease of the skin developing in the presence of excess sebum production and clogged hair follicles, beginning as comedones and potentially developing into papules and pustules in mild to moderate conditions. Consistent and continuous use of a daily acne regimen is an important line of therapy to effectively control the acne condition. This study assesses the efficacy of two separate acne treatment regimens following a 12-week clinical study. A single-blind, investigator-masked, randomized, multicenter study was conducted to evaluate the efficacy of a regimen consisting of a retinoid-based acne treatment cream with ancillary cleanser and moisturizing lotion compared to an acne treatment regimen based in benzoyl peroxide and salicylic acid. Assessments were made using clinical evaluations and self-assessment questionnaires at baseline and weeks 2, 4, 8, and 12. A total of 160 males and females 12 to 30 years of age with mild to moderate acne vulgaris completed this study. One treatment group used a regimen with a 10% benzoyl peroxide cleanser, 2% salicylic acid microgel complex, and a 0.5% salicylic acid lotion. A second treatment group used a multiproduct regimen with a retinoid-based cream. Clinical assessments showed improvements in global acne and total lesion counts for both regimens over 12 weeks. The areas of superiority and those parameters with comparable improvements between the two regimens provide dermatologists with valuable insights in designing therapies for specific patients. Commercial support: 100% sponsored by Johnson & Johnson Consumer & Personal Products Worldwide.
Background: Patient-reported assessments are important in evaluating new treatments for acne and a good indicator of increased patient adherence and outcome. Objective: To evaluate the onset and magnitude of improvement achieved with a unique combination of clindamycin phosphate and low concentration benzoyl peroxide (clindamycin-BPO 2.5%) from the subject’s perspective. Methods: Two multicenter double-blind studies in 2813 subjects with moderate to severe acne randomized 2:2:2:1 to receive a combination of clindamycin phosphate (1.2%) and benzoyl peroxide (2.5%), each active ingredient or vehicle, once daily for 12 weeks. Subject Self-Assessment (SSA) of acne severity and degree of improvement were evaluated on a scale from one (clear) to seven (worse) at each postbaseline visit. Subject satisfaction with treatment was evaluated on a scale from one (least satisfied) to ten (most satisfied) at baseline and end of treatment. Results: As early as week 2, a significantly greater number of subjects rated their acne as ‘‘clear’’’ or ‘‘almost clear’’ with clindamycin-BPO 2.5% compared with benzoyl peroxide (P ¼.045) and vehicle (P ¼.002); this difference increased through week 12. At week 12, clindamycin-BPO 2.5% was statistically superior (P\.001 vs all other treatment groups) in the percent of subjects who rated their acne as ‘‘clear’’ or ‘‘almost clear’’ (39.2%) compared with 29.6% on clindamycin phosphate 1.2%, 29.7% on BPO 2.5%, and 16.6% on vehicle. Subjects also reported greater satisfaction with treatment using clindamycin-BPO 2.5% at week 12 than with individual active ingredients or vehicle. The percent of subjects completing the study was highest in the clindamycin-BPO 2.5% group. Conclusions: Based upon patient-reported outcomes, the unique fixed combination clindamycin-BPO 2.5% aqueous gel applied once daily is an effective therapy for subjects with moderate to severe inflammatory and noninflammatory acne. Significant results are seen as early as week 2. By providing rapid and beneficial improvements in acne as perceived by patients, the use of clindamycin-BPO 2.5% may lead to increased patient adherence to treatment and, therefore, to improved clinical outcomes. Commercial support: 100% sponsored by Arcutis Pharmaceuticals Inc.
P723 The effect of Er: glass fractional laser and chemical reconstruction of skin scar (CROSS) method in treatment of acne scars: A simultaneous split-face comparison study HeeJung Kim, MPH, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, SeodaemunGu, South Korea; EunChun Han, MD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; JuHee Lee, MD, PhD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; KwangHoon Lee, MD, PhD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea; TaeGyun Kim, MD, Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Seodaemun-Gu, South Korea Background: Acne scars are a common skin condition, but treatment of acne scars are a well known challenge for dermatologists. Numerous treatment options have been proposed. However, there has been no well controlled study comparing the efficacy of 1550nm Er: glass laser and the chemical reconstruction of skin scar (CROSS) method. Objective: We designed the study to compare the efficacy of 1550nm Er: glass fractional laser and CROSS method in the treatment of moderate to severe acne scars. Methods: A split-face trial was conducted in 20 patients with moderate to severe acne scars. One side of the face was treated with 1550-nm Er: glass laser and the other side was treated with CROSS method using 100% trichloroacetic acid for 3 months. Overall effects and side effects were monitored during 12 weeks and after the final treatment session using photography with digital camera, folliscope findings, and 10-point scale assessment evaluated by two individual dermatologists. Patient’s subjective self-assessment was also evaluated. Results: After all of the treatment, statistically significant improvement was demonstrated in both sides of the face. There were no significant differences between both treatment options regarding patient satisfaction. However, it was evident that the 1550-nm Er: glass laser had greater effect on rolling scars, while CROSS method had greater effect on icepick scars. Downtime and lasting erythema were much longer remained in CROSS method group. And there were no significant side effects in 1550-nm Er: Glass laser group. Just one pustule formation and one hyperpigmentation were observed in CROSS method group. Conclusions: A 1550-nm Er: glass fractional laser and CROSS method are both well tolerated and effective treatment options for the treatment of acne scars. However, the objective results demonstrated different effects dependent upon the scar type. Therefore, it may be important to consider the type of acne scar preliminary to select the treatment option. Commercial support: None identified.
AB18
J AM ACAD DERMATOL
P725 Impact of acne on teens: Results from Harris Interactive poll Alan Fleischer, Wake Forest University School of Medicine, Winston-Salem, NC, United States Acne often leads to dissatisfaction with one’s personal appearance. A national survey of teens with acne measured the importance of appearance, impact of acne on individuals’ lives, how people treat acne, and level of knowledge about skin care. Subjects were recruited from the Harris Poll Online database. The 2732 US respondents comprised 1327 teens (13-19 yrs of age) and 514 adults (20-40 yrs of age) with acne, 628 parents of teens with acne, and 263 dermatologists. The survey was conducted in December 2007. Most teens (70%) feel pressure to have clear skin. After weight (32%), skin is the physical attribute that 16% say they would most like to change. Those who have had acne say the more severe the acne the more it impacts self-confidence (69% severe/moderate vs 42% mild), mood (54% vs 28%), and feeling of stress (48% vs 24%). Acne tends to have a greater negative impact on girls than boys. Teens with acne are less happy (mild, 83%; severe/moderate, 74%) than teens without acne (86%), but compared to teens without acne they seem to have better grades in school (33% vs 13%) and greater participation in weekly extracurricular activities (91% vs 74%). Although acne is perceived as a health care issue, 56% of all teen subjects and 54% with more severe/moderate acne are not very knowledgeable about skin care. Only 25% of teens with acne have visited a physician and only 14% have seen a dermatologist. When teens do visit a physician, 63% of teens, 74% of parents, and 43% of dermatologists report that parents initiated the first appointment. Teens (89%) and dermatologists (97%) believe that acne is controllable. But dermatologists (91%) view patient compliance as a treatment barrier, and only 2% say patients follow treatment as prescribed. Half of teens who use acne medications (52%) say they adhere to treatment. Physicianepatient communication is considered satisfactory by 46% of teens who have seen a physician; however, 69% of dermatologists are satisfied. These findings suggest a communication gap among teens and physicians. Despite the availability of improved, effective therapeutic agents, teens continue to suffer the negative impact of acne on quality of life and social relationships. Better communication may help to increase compliance and reduce the impact of acne. Commercial support: Harris Interactive Poll sponsored by OrthoNeutrogena; poster printing costs sponsored by OrthoNeutrogena.
MARCH 2009